The role of AXL and the <i>in vitro</i> activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma
Emmy D.G. Fleuren(Radboud University Medical Center), Yvonne M.H. Versleijen‐Jonkers(Radboud University Nijmegen)
Cited by 47
Related Papers
Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507
|Clinical Cancer Research|2011|42
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
|Targeted Oncology|2017|39
Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes
|Cancer Research|2017|35
Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models
|International Journal of Cancer|2014|21
Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups
|Immunologic Research|2022|15